PG国际

Leadership
Board of Directors
Management Team
Henlius has assembled a team of highly-skilled talents with extensive experience across research & development, clinical development, manufacturing, commercialisation, regulatory affairs, CMC, quality and compliance, etc. at leading multinational pharmaceutical companies.
Dr. Jun Zhu
Executive Director
Dr. Xingli Wang
Chairman & Non-executive Director
Mr. Qiyu Chen
Non-executive Director
Mr. Yuqing Chen
Non-executive Director
Ms. Xiaohui Guan
Non-executive Director
Dr. Yi Liu
Non-executive Director
Mr. Tak Young So
Independent Non-executive Director
Dr. Lik Yuen Chan
Independent Non-executive Director
Dr. Ruilin Song
Independent Non-executive Director
Dr. Jason Zhu is the Executive Director and Chief Executive Officer. Jason has more than 20 years in clinical research industry. He had cooperated with over 70 China local pharmaceutical and biotech companies and led the design and execution of over 100 phase I to IV clinical trials. Prior to joining Henlius, Jason was Founder and CEO of PPC China, Global Vice President of IQVIA, China GM of Omnicare. Jason had previously worked as a physician in Huashan Hospital for two years. 
" />
Jason Zhu
Executive Director & Chief Executive Officer
Ms. Wei Huang, President, is in charge of the Global Manufacturing Engineering Technology Department, responsible for the production and supply of the Company's clinical and commercial products, the design and implementation of engineering projects, and the continuous improvement and optimization of production capacit. Ms. Huang holds Bachelor degree from East China University of Science and Technology in Biochemical Engineering, Master degree from University of Maryland in Chemical and Biochemical Engineering. Prior to joining Henlius, Ms. Huang has Senior management and leadership experience in pharmaceutical and biotechnology industry spanning over 30 years in process development, technology transfer, manufacturing, process and facility design, capital project execution, and quality system implementation.
" />
Wei Huang
President
Mr. Kurt Yu, Senior Vice President and Chief Commercial Officer, is in charge of the Marketing and Commercial Operations Department and the Medical Affairs Department, responsible for the commercial operations. Prior to joining Henlius, Mr. Yu has over 20 years’ experience in sales and central marketing management (for Glaxo Wellcome, Roche and Amgen) with different roles including medical representative, product manager, district sales manager, marketing manager, and marketing director/ head. He has rich experience in portfolio management, marketing strategy development, new product launch etc.

Mr. Yu graduated from Shanghai Medical University with bachelor degree in pharmaceutical chemistry. Then he obtained the EMBA degree from Fudan University.
" />
Kurt Yu
Chief Commercial Officer & SVP
Ms. Ping Cao, Senior Vice President and Chief Business Development Officer, is in charge of the Business Development Department, responsible for the Company's business cooperation with external partners, including licensing in and out, authorization, partnership alliance, merger and acquisition. Ms. Cao graduated from Tianjin University with a BS in Material Science & Engineering and MS in Chemical Engineering and obtained her MS in Organic Chemistry at Michigan State University. She previously worked at Tyger Scientific, Ferro, Bristol-Myer Squibb (BMS) and Abzena, and held positions of Director of Sales and Marketing, Sr. Manager of Business Development, Associate Director of Global Manufacturing and Supply Chain, and Sr. Director of Business Development. At Tyger Scientific, Ms. Cao increased the business revenue 600% in 4 years. At BMS, she was responsible for global business development at CMO (contract manufacture operation) and accomplished significant sales growth. Then Ms. Cao joined business development team focusing on technology transactions. She evaluated, negotiated and executed 36 technology collaboration deals to expedite the company’s drug discovery and development process. As a reward for her accomplishment, Ms. Cao received the Distinguished Employee Award, Innovation Award etc. at BMS. At Abzena, she developed and executed the business strategy of offering integrated contract manufacture service of biologics and antibody drug conjugates based on company core technologies of antibody drug conjugation and humanization, which greatly enhanced the company’s business growth worldwide.
" />
Ping Cao
Chief Business Development Officer & SVP
Dr. Simon Hsu holds PhD degree from Purdue University in Biochemical Engineering, Master degree from Ohio State University in Biochemical Engineering, and Bachelor degree from National Tsing Hua University in Chemical Engineering. Dr. Simon Hsu has over 2 8 years of management and research experience in the pharmaceutical industry . He has directed and successfully managed more than 25 antibody and recombinant protein projects of technology transfer, scale up and process validation up to 40,000 L Prior to joining Henlius, he served for leading enterprise in pharmaceuticals ind ustry, such as GenSci , HuiGene Therapeutics , Henlius, Pieris, Shire, Bristol Myers Squibb MedImmune AstraZeneca )), Alexion AstraZeneca etc . Dr. Simon Hsu has extensive experience and technology in process development, production, quality control, project management, international registration, licensing applications, clinical to market commercialization, and continuous bioprocess etc.
" />
Simon Hsu
Chief Technology Officer & SVP
James Guo
SVP
Ms. Jessie Li, Senior Vice President and Chief Human Resource Officer, is responsible for overall HR strategy, organization development, talent strategy. Ms. Jessie Li brings with her over 20 years of HR management experiences, and prior to joining Henlius, she worked in TCCP, Astra Zeneca, De Lage Landen, Kodak Healthgroup/Carestream as HRVP, Executive HR Director, Head of China HR. Ms. Jessie Li holds Bachelor degree from Shandong Finance University in International Finance in 1998, and MBA from Shanghai University of Finance and Economics – Webster University in 2002.
" />
Jessie Li
Chief Human Resource Officer & SVP
Dr. Jiyun Yuan, Chief Scientific Officer (CSO), is responsible for the overall strategic planning, team management and daily operations of Innovation Center. Dr. Yuan has extensive experience and outstanding achievements in leading innovative drug research and development and building innovative early research team. He has achieved remarkable results in preclinical research and development, clinical trial applications, patent applications and intellectual property transfers of antibody drugs. Dr. Yuan’s research and development work covers a wide range of drugs, including antibodies, CAR-T, mRNA, and small molecules etc. Prior to joining Henlius, Dr. Yuan  served as Deputy Director of Biology Department of Shanghai Hengrui Medical Co., Ltd., Vice President & Chief Scientific Officer of Shanghai Genechem Co., Ltd., General Manager of Shanghai Genbase Biotechnology Co., Ltd. (wholly owned subsidiary of Shanghai Genechem Co., Ltd.), and President of Preclinical Development of Suzhou Abogen Biosciences Co., Ltd. Dr. Yuan holds a Ph.D. in Biochemistry from The Ohio State University in the United States and completed his postdoctoral research in Molecular Biology at the University of California. He earned his bachelor's degree in Biochemistry from Fudan University.
" />
Jijun Yuan
Chief Scientific Officer
Cindy Shen
Chief Quality Officer & VP

" />
Max Mao
Chief Financial Officer & VP
Ming Yang
VP of Immune-Oncology Business Unit
Mr. Jing Li, Vice President of Global Product Development, is responsible for the global strategic planning and operational management of Global Product Development Department. During over 15 years on clinical research, he has successfully launched the first biosimilar drug in China (HANLIKANG), the first EMA approved biologic product from China (HANQUYOU), and managed over 80 clinical trials, covering clinical phase 1 to Phase 4 trials. Before joining Henlius, he worked for Hutchison, Roche, Covance and SPH. He has the master's degree of medicine from Tongji University.
" />
Jing Li
VP of Global Product Development
Ms. Li Jin, Vice President of Regulatory Affairs, is responsible for the global strategic planning and operational management of Regulatory Affairs Department. Ms. Li Jin graduated from Beijing University of Chinese Medicine with a Bachelor’s degree in Traditional Chinese Medicine. She has about 22 years experience in regulatory affairs. Prior to joining Henlius, she held the key position in many different types of companies, including local and multi-national ones, for example Nuance, Mundi Pharma, Merck Serono, Amgen, MSD and China Grand Enterprises, etc. She also had 5 years medicine research experience in pharmaceutical R&D center. Her ability to control different stages of different products is excellent due to previous experienced in various types of companies, including small molecular, biological and medical device products, etc. In addition, she has rich team management skill, especially on team building up and member development. 
" />
Jin Li
VP of Regulatory Affairs
Miaojie Chen
VP of Legal and Compliance
Nancy Wang
Board Secretary & VP
Qingyu Wang
Chief Medical Officer
Darius Panaligan
Chief Commercial Officer, International Markets
Guangri Sun
GM of Oncology Business Unit
K. Christopher Garcia
Scientific Advisory Board
Kun-Liang Guan
Scientific Advisory Board
Yang-Xin Fu
Scientific Advisory Board
Lixin Zhang
Scientific Advisory Board

" />
Alberto Mantovani
Scientific Advisory Board
Jun Wang
Scientific Advisory Board
Back
Dr. Jun Zhu
Executive Director

Dr. Jun Zhu, aged 45, has joined the Group since December 2020, and currently serves as the Executive Director and?Chief Executive Officer of the Company and holds directorship and other positions in certain subsidiaries of the Company?and holds directorship and other positions in certain subsidiaries of the Company.

 

Before joining the Group, Dr. Zhu served as the internal medicine physician in Huashan Hospital affiliated to Fudan University in Shanghai, the project manager and global vice-president of IQVIA Holdings Inc., the general manager in Greater China of Omnicare Clinical Research Inc., the founder and chief executive officer of Shanghai PPC Biopharmaceutical Technology Co., Ltd.*(上海百利佳生醫藥科技有限公司).

 

Dr. Zhu obtained a bachelor’s degree in clinical medicine from Fudan University (復旦大學) in China in July 2001, an EMBA degree from Cheung Kong Graduate School of Business (長江商學院) in China in September 2018 and a doctoral degree in health management from University of Montpellier in June 2024.

  1. Home
  2. About
  3. Dr. Jun Zhu
Back
Privacy Policy
Cookies Policy
Accessibility
Terms of Use
  1. Home
【网站地图】